Literature DB >> 24338112

Use of different parameters and equations for calculation of IC₅₀ values in efflux assays: potential sources of variability in IC₅₀ determination.

Donna A Volpe1, Salaheldin S Hamed, Lei K Zhang.   

Abstract

Drug interactions due to efflux transporters may result in one drug increasing or decreasing the systemic exposure of a second drug. The potential for in vivo drug interactions is estimated through in vitro cell assays. Variability in in vitro parameter determination (e.g., IC₅₀ values) among laboratories may lead to different conclusions in in vivo interaction predictions. The objective of this study was to investigate variability in in vitro inhibition potency determination that may be due to calculation methods. In a Caco-2 cell assay, the absorptive and secretive permeability of digoxin was measured in the presence of spironolactone, itraconazole and vardenafil. From the permeability data, the efflux ratio and net secretory flux where calculated for each inhibitor. IC₅₀ values were then calculated using a variety of equations and software programs. All three drugs decreased the secretory transport of digoxin in a concentration-dependent manner while increasing digoxin's absorption to a lesser extent. The resulting IC₅₀ values varied according to the parameter evaluated, whether percent inhibition or percent control was applied, and the computational IC₅₀ equation. This study has shown that multiple methods used to quantitate the inhibition of drug efflux in a cell assay can result in different IC₅₀ values. The variability in the results in this study points to a need to standardize any transporter assay and calculation methods within a laboratory and to validate the assay with a set of known inhibitors and non-inhibitors against a clinically relevant substrate.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24338112      PMCID: PMC3889528          DOI: 10.1208/s12248-013-9554-7

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  51 in total

1.  Comparison of P-glycoprotein-mediated drug-digoxin interactions in Caco-2 with human and rodent intestine: relevance to in vivo prediction.

Authors:  Andrew Collett; Jola Tanianis-Hughes; Gordon L Carlson; Matthew D Harwood; Geoff Warhurst
Journal:  Eur J Pharm Sci       Date:  2005-09-08       Impact factor: 4.384

2.  Evaluation of inhibitory potencies for compounds inhibiting P-glycoprotein but without maximum effects: f2 values.

Authors:  Johanna Weiss; Walter Emil Haefeli
Journal:  Drug Metab Dispos       Date:  2005-11-04       Impact factor: 3.922

Review 3.  Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants.

Authors:  Aline H Saad; Daryl D DePestel; Peggy L Carver
Journal:  Pharmacotherapy       Date:  2006-12       Impact factor: 4.705

Review 4.  Current industrial practices of assessing permeability and P-glycoprotein interaction.

Authors:  Praveen V Balimane; Yong-Hae Han; Saeho Chong
Journal:  AAPS J       Date:  2006-01-13       Impact factor: 4.009

Review 5.  Variability in Caco-2 and MDCK cell-based intestinal permeability assays.

Authors:  Donna A Volpe
Journal:  J Pharm Sci       Date:  2008-02       Impact factor: 3.534

6.  In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates.

Authors:  Jarkko Rautio; Joan E Humphreys; Lindsey O Webster; Anand Balakrishnan; John P Keogh; Jeevan R Kunta; Cosette J Serabjit-Singh; Joseph W Polli
Journal:  Drug Metab Dispos       Date:  2006-02-02       Impact factor: 3.922

7.  Effect of cell differentiation and passage number on the expression of efflux proteins in wild type and vinblastine-induced Caco-2 cell lines.

Authors:  Sanna Siissalo; Leena Laitinen; Maija Koljonen; Kati-Sisko Vellonen; Hanna Kortejärvi; Arto Urtti; Jouni Hirvonen; Ann Marie Kaukonen
Journal:  Eur J Pharm Biopharm       Date:  2007-03-28       Impact factor: 5.571

8.  Effect of P-glycoprotein expression levels on the concentration-dependent permeability of drugs to the cell membrane.

Authors:  Yoshiyuki Shirasaka; Toshiyasu Sakane; Shinji Yamashita
Journal:  J Pharm Sci       Date:  2008-01       Impact factor: 3.534

9.  Role of p-glycoprotein inhibition for drug interactions: evidence from in vitro and pharmacoepidemiological studies.

Authors:  Sonja Eberl; Bertold Renner; Antje Neubert; Mareike Reisig; Iouri Bachmakov; Jörg König; Frank Dörje; Thomas E Mürdter; Andreas Ackermann; Harald Dormann; Karl G Gassmann; Eckhart G Hahn; Stefanie Zierhut; Kay Brune; Martin F Fromm
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

10.  In vitro-to-in vivo prediction of P-glycoprotein-based drug interactions at the human and rodent blood-brain barrier.

Authors:  Peng Hsiao; Tot Bui; Rodney J Y Ho; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2007-12-05       Impact factor: 3.922

View more
  8 in total

1.  Acidosis potentiates endothelium-dependent vasorelaxation and gap junction communication in the superior mesenteric artery.

Authors:  Ipsita Mohanty; Subas Chandra Parija; Sujit Suklabaidya; Satish Rattan
Journal:  Eur J Pharmacol       Date:  2018-03-07       Impact factor: 4.432

2.  Modeling the Ethanol Tolerance of the Probiotic Yeast Saccharomyces cerevisiae var. boulardii CNCM I-745 for its Possible Use in a Functional Beer.

Authors:  G Yedid Ramírez-Cota; E Oliver López-Villegas; Antonio R Jiménez-Aparicio; Humberto Hernández-Sánchez
Journal:  Probiotics Antimicrob Proteins       Date:  2021-02       Impact factor: 4.609

3.  IMPDH1 retinal variants control filament architecture to tune allosteric regulation.

Authors:  Anika L Burrell; Chuankai Nie; Meerit Said; Jacqueline C Simonet; David Fernández-Justel; Matthew C Johnson; Joel Quispe; Rubén M Buey; Jeffrey R Peterson; Justin M Kollman
Journal:  Nat Struct Mol Biol       Date:  2022-01-10       Impact factor: 18.361

Review 4.  Role of OATP1B1 and OATP1B3 in Drug-Drug Interactions Mediated by Tyrosine Kinase Inhibitors.

Authors:  Dominique A Garrison; Zahra Talebi; Eric D Eisenmann; Alex Sparreboom; Sharyn D Baker
Journal:  Pharmaceutics       Date:  2020-09-09       Impact factor: 6.321

5.  A study of the dopamine transporter using the TRACT assay, a novel in vitro tool for solute carrier drug discovery.

Authors:  Hubert J Sijben; Julie J E van den Berg; Jeremy D Broekhuis; Adriaan P IJzerman; Laura H Heitman
Journal:  Sci Rep       Date:  2021-01-14       Impact factor: 4.379

6.  Anti-proliferative and apoptotic effects of hull-less pumpkin extract on human papillary thyroid carcinoma cell line.

Authors:  Mohammad Hadi Bahadori; Zoleikha Azari; Arash Zaminy; Sara Dabirian; Seyed Mojtaba Mehrdad; Bahman Jalali Kondori
Journal:  Anat Cell Biol       Date:  2021-03-31

7.  The cytotoxicity and apoptotic effects of verbascoside on breast cancer 4T1 cell line.

Authors:  Atena Daneshforouz; Samad Nazemi; Omid Gholami; Marzieh Kafami; Bahareh Amin
Journal:  BMC Pharmacol Toxicol       Date:  2021-11-29       Impact factor: 2.483

8.  Ropivacaine-Loaded Poloxamer Binary Hydrogels for Prolonged Regional Anesthesia: Structural Aspects, Biocompatibility, and Pharmacological Evaluation.

Authors:  Kelli Cristina Freitas Mariano; Juliana Zampoli Boava Papini; Naially Cardoso de Faria; Daniele Nicoli Cabral Heluany; Ana Luiza Lourençoni Botega; Cíntia Maria Saia Cereda; Eneida de Paula; Giovana Radomille Tófoli; Daniele Ribeiro de Araujo
Journal:  Biomed Res Int       Date:  2021-09-16       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.